New proteasome inhibitors in the treatment of multiple myeloma
Hematol., Transfus. Cell Ther. (Impr.)
; 41(1): 76-83, Jan.-Mar. 2019. tab, ilus
Artigo
em Inglês
| LILACS
| ID: biblio-1002040
Biblioteca responsável:
BR408.1
Localização: BR408.1
ABSTRACT
Abstract The treatment of patients with relapsed and/or refractory multiple myeloma has improved considerably in the last 15 years, after the introduction of proteasome inhibitors and immunomodulatory drugs. The first clinical trials with new proteasome inhibitors have produced exciting results, particularly those comparing triplet regimens with standard doublet regimens, with a gain in progression-free survival accompanied by an acceptable safety profile and either similar or better health-related quality of life. New proteasome inhibitors hold the potential to fill unmet needs in multiple myeloma management regarding improvement of clinical outcomes, including delayed progression of disease in high-risk patients. This review summarizes the main pharmacological properties and clinical outcomes of these agents, and discusses their potential to change the whole multiple myeloma therapeutic landscape.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
LILACS
Assunto principal:
Inibidores de Proteassoma
/
Mieloma Múltiplo
Aspecto:
Preferência do paciente
Idioma:
Inglês
Revista:
Hematol., Transfus. Cell Ther. (Impr.)
Assunto da revista:
Hematologia
/
TransfusÆo de Sangue
Ano de publicação:
2019
Tipo de documento:
Artigo
País de afiliação:
Brasil
Instituição/País de afiliação:
Evidências - Kantar Health/BR
/
Hospital Israelita Albert Einstein/BR
/
Hospital de Clínicas de Porto Alegre/BR
/
Santa Casa de São Paulo/BR
/
Takeda Pharma/BR
/
Universidade Católica de Brasília/BR
/
Universidade Federal da Bahia - UFBA/BR
/
Universidade Federal do Rio de Janeiro - UFRJ/BR